Hence, FASN inhibitors enabled breast cancer cells to be sensitive to venetoclax or navitoclax to overcome the insensitivity of monotherapy with BCL-2 inhibitors in vivo [131]. This evidence concerns the gene BCL2 and breast carcinoma.